ICTD 2023 - Decentralised Clinical Trials - Industry Perspective- Ekata Shah

Ekata Shaw discussed for the industry what it can represent to be a sponsor of a DCT and what the implications and considerations necessary to choose between a full vs hybrid DCT. She highlighted the importance of having the capacity to run such trials (both human resources and finances). She went on to explain that the decentralised elements are about giving patients choices and not about adding complicated elements.